Replimune Group, Inc. (NASDAQ:REPL) Receives $19.14 Average Target Price from Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL) have received a consensus rating of “Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $19.14.

A number of research firms have recently commented on REPL. HC Wainwright upped their price objective on shares of Replimune Group from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, January 22nd. Jefferies Financial Group raised their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets raised their price target on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd.

Insider Activity

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several large investors have recently added to or reduced their stakes in REPL. Charles Schwab Investment Management Inc. boosted its holdings in Replimune Group by 12.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock valued at $5,313,000 after acquiring an additional 52,498 shares during the period. Geode Capital Management LLC lifted its stake in shares of Replimune Group by 17.9% in the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after buying an additional 217,308 shares in the last quarter. Barclays PLC lifted its stake in Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after acquiring an additional 98,791 shares during the period. LMR Partners LLP boosted its stake in shares of Replimune Group by 145.8% in the 3rd quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock worth $904,000 after buying an additional 48,920 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after purchasing an additional 2,656,173 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Up 2.4 %

Shares of NASDAQ:REPL opened at $14.02 on Friday. The firm has a market cap of $959.25 million, a P/E ratio of -4.60 and a beta of 1.28. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00. The business has a fifty day simple moving average of $12.40 and a 200 day simple moving average of $11.42. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Analysts predict that Replimune Group will post -2.88 earnings per share for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.